We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
-9.85%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
AUM
$110M
AUM Growth
-$25.2M
Cap. Flow
+$1.67M
Cap. Flow %
1.52%
Top 10 Hldgs %
66.13%
Holding
26
New
5
Increased
2
Reduced
2
Closed
4
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VERV
26
DELISTED
Verve Therapeutics
VERV
-105,360
Closed -$2.4M

Similar funds

Ally Bridge Group's Q2 2022 Portfolio in Review

As of Q2 2022, Ally Bridge Group held 26 positions worth $110M, down 19% from $135M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Ally Bridge Group's Q2 2022 filing shows 5 new, 2 increased, 2 reduced and 4 closed positions. Its largest new stake was argenx: 39,370 shares worth $14.9M. The largest sale was Lantheus, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Ally Bridge Group's largest Q2 2022 buy was argenx: 39,370 shares worth $14.9M.
  • Ally Bridge Group added most to MedAvail Holdings, Inc. Common Stock in Q2 2022, an estimated $5.22M increase.
  • Ally Bridge Group's biggest Q2 2022 reduction was Lantheus, cutting an estimated $10.7M.
  • Ally Bridge Group fully exited Arvinas in Q2 2022, selling an estimated $10.1M.
  • Ally Bridge Group's ten largest holdings make up 66% of its $110M portfolio in Q2 2022.
  • Ally Bridge Group opened 5 new positions and closed 4 in Q2 2022.
  • Ally Bridge Group's portfolio value fell 19% quarter-over-quarter to $110M.

Based on Ally Bridge Group's 13F filing for Q2 2022, filed 15 Aug 2022.